Specialty medical injectable drug program, requirements and drug policy updates: Cimerli™ and Skyrizi®
New specialty medical injectable updates and requirements announced.
Sept. 22, 2022
Please review the following table to determine changes to our specialty medical injectable drug programs.
Specialty medical injectable drugs added to review at launch
| Drug Name | UnitedHealthcare Commercial | Treatment Uses |
|---|---|---|
| Cimerli™ (ranibizumab-eqrn) |
X | Indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization. |
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
Updates to drug program requirements and drug policies for UnitedHealthcare commercial business effective Nov. 1, 2022
| Drug Name | Treatment Uses | Summary of Changes |
|---|---|---|
| Skyrizi® – IV formulation (risankizumab-rzaa) |
Used to treat adults with moderate to severe Crohn’s disease. | Add notification/prior authorization and Site of Care. Note: Subcutaneous self-administered Skyrizi is covered under the pharmacy benefit. |
For questions, please contact your broker or UnitedHealthcare representative.
More articles
Broker - Page template - More news Experience Fragment
